November 15, 2016 - By Vivian Park · 0 Comments
The stock of Sangamo Biosciences Incorporated (NASDAQ:SGMO) registered a decrease of 12.17% in short interest. SGMO’s total short interest was 7.64 million shares in November as published by FINRA. Its down 12.17% from 8.69 million shares, reported previously. With 1.02 million shares average volume, it will take short sellers 8 days to cover their SGMO’s short positions. The short interest to Sangamo Biosciences Incorporated’s float is 11.81%. About 540,688 shares traded hands. Sangamo Biosciences, Inc. (NASDAQ:SGMO) has declined 34.63% since April 13, 2016 and is downtrending. It has underperformed by 38.55% the S&P500.
Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $317.73 million. The Firm is focused on research, development and commercialization of engineered deoxyribonucleic acid -binding proteins for therapeutic genome editing and gene regulation. It currently has negative earnings. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.
Insitutional Activity: The institutional sentiment decreased to 0.81 in Q2 2016. Its down 0.57, from 1.38 in 2016Q1. The ratio worsened, as 20 funds sold all Sangamo Biosciences, Inc. shares owned while 42 reduced positions. 13 funds bought stakes while 37 increased positions. They now own 45.72 million shares or 4.72% less from 47.99 million shares in 2016Q1.
Moreover, Renaissance Technology Limited has 0% invested in Sangamo Biosciences, Inc. (NASDAQ:SGMO) for 114,200 shares. Employees Retirement Association Of Colorado last reported 0% of its portfolio in the stock. Quantitative Systematic Strategies Ltd Liability accumulated 0.08% or 28,176 shares. Proshare Advsrs Limited Liability accumulated 60,971 shares or 0% of the stock. Fincl Bank Of New York Mellon has 3.34M shares for 0.01% of their US portfolio. Leisure Capital Mngmt accumulated 0.28% or 42,452 shares. Alliancebernstein Limited Partnership has invested 0% of its portfolio in Sangamo Biosciences, Inc. (NASDAQ:SGMO). Beacon Cap Mngmt accumulated 0% or 4,950 shares. Raymond James Fincl Inc, a Florida-based fund reported 12,783 shares. Qs Limited Liability Corporation holds 0.01% of its portfolio in Sangamo Biosciences, Inc. (NASDAQ:SGMO) for 145,236 shares. Bankshares Of America Corp De has 0% invested in the company for 29,157 shares. Cannell Peter B & Company has 0.01% invested in the company for 31,750 shares. Teacher Retirement System Of Texas owns 9,268 shares or 0% of their US portfolio. Metropolitan Life Insur Co holds 0% of its portfolio in Sangamo Biosciences, Inc. (NASDAQ:SGMO) for 47,865 shares. Highbridge Capital Mgmt Ltd Llc last reported 0.01% of its portfolio in the stock.
Out of 9 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 4 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 44% are positive. Sangamo Biosciences has been the topic of 12 analyst reports since August 8, 2015 according to StockzIntelligence Inc. The stock has “Overweight” rating given by JP Morgan on Saturday, August 8. Jefferies maintained the stock with “Buy” rating in Wednesday, September 2 report. The firm has “Buy” rating given on Friday, October 23 by Jefferies. The stock of Sangamo Biosciences, Inc. (NASDAQ:SGMO) earned “Neutral” rating by Wedbush on Tuesday, November 1. On Wednesday, October 19 the stock rating was downgraded by Piper Jaffray to “Neutral”. Wedbush maintained the shares of SGMO in a report on Wednesday, September 2 with “Buy” rating. The rating was maintained by Cowen & Co with “Buy” on Friday, September 4. The stock of Sangamo Biosciences, Inc. (NASDAQ:SGMO) earned “Outperform” rating by Wells Fargo on Friday, December 4. The firm earned “Neutral” rating on Wednesday, October 19 by PiperJaffray. The stock has “Buy” rating given by JP Morgan on Thursday, September 3.
Sangamo Biosciences Inc., incorporated on June 22, 1995, is a clinical-stage biopharmaceutical company. The Firm is focused on the research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. The Firm is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics, which are therapeutic products for the treatment of genetic disease. The Company’s ZFP Therapeutic, SB-728, a ZFP nuclease (ZFN)-modified autologous cell product for the treatment of Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS), is the therapeutic application of its ZFN genome editing technology and is being evaluated in an ongoing Phase II study of ZFN-modified T-cells (SB-728-T-1101, Cohort 3) and a Phase I/II study of modified hematopoietic stem cells (SB-728mR-HSPC) in HIV-infected subjects. The Firm has preclinical programs in hemophilia A and other Lysergic acid diethylamide (LSDs), and research stage programs in other monogenic diseases, including certain central nervous system (CNS) disorders and cancer immunotherapy.
More notable recent Sangamo Biosciences, Inc. (NASDAQ:SGMO) news were published by: Fool.com which released: “Why Sangamo Biosciences, Inc. Fell 29% Today” on August 04, 2016, also Prnewswire.com with their article: “Sangamo BioSciences Announces Third Quarter 2016 Conference Call and Webcast” published on October 19, 2016, Prnewswire.com published: “Sangamo BioSciences Announces Participation In Upcoming Scientific Conferences” on October 17, 2016. More interesting news about Sangamo Biosciences, Inc. (NASDAQ:SGMO) were released by: Prnewswire.com and their article: “Sangamo BioSciences Announces Retirement Of Edward Lanphier As President And …” published on June 01, 2016 as well as Prnewswire.com‘s news article titled: “Sangamo BioSciences Receives Orphan Drug Designation From The FDA For SB-FIX …” with publication date: September 06, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Vivian Park